Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Gerald W PragerJulien TaiebMarwan FakihFortunato CiardielloEric Van CutsemElena ElezFelipe M CruzLucjan WyrwiczDaniil StroyakovskiyZsuzsanna PápaiPierre-Guillaume PoureauGabor LipositsChiara CremoliniIgor BondarenkoDominik P ModestKarim A BenhadjiNadia AmellalCatherine LegerLoïck VidotJosep Taberneronull nullPublished in: The New England journal of medicine (2023)
Among patients with refractory metastatic colorectal cancer, treatment with FTD-TPI plus bevacizumab resulted in longer overall survival than FTD-TPI alone. (Funded by Servier and Taiho Oncology; SUNLIGHT ClinicalTrials.gov number, NCT04737187; EudraCT number, 2020-001976-14.).